<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="190">
  <stage>Registered</stage>
  <submitdate>12/08/2005</submitdate>
  <approvaldate>15/08/2005</approvaldate>
  <actrnumber>ACTRN12605000152628</actrnumber>
  <trial_identification>
    <studytitle>A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual disease</studytitle>
    <scientifictitle>A phase II trial of high dose cytarabine and fludarabine without anthracycline for patients with core binding factor acute myeloid leukaemia, measuring efficacy, safety and monitoring minimal residual disease</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Australasian Leukaemia and Lymphoma Group (ALLG): ALLG AMLM13</secondaryid>
    <secondaryid>National Clinical Trials Registry: NCTR555</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Core binding factor acute myeloid leukaemia</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with CBF leukaemia will be treated with high dose Cytarabine and Fludarabine chemotherapy. An induction course will be followed by 6 consolidation cycles 3 of which are Cytarabine alone and 3 of which are fludarabine &amp; cytarabine in combination but in lower total doses than in the induction cycle. Total treatment time will be 7 to 9 months. In addition, minimal residual disease will be monitored using sensitive laboratory methods at 1 and 3 monthly intervals for blood and bone marrow respectively.</interventions>
    <comparator>there is no compatator/control treatment in this trial</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To establish the failure-free (FFS) rates of patients with newly diagnosed core binding factor (CBF) acute myeloid leukaemia (AML) treated with high-dose cytarabine (Ara-C) containing regimens exclusive of anthracyclines.</outcome>
      <timepoint>The first analysis of FFS will take place 12 months after the last-registered patient has commenced treatment.  If appropriate, the final analysis will take place after all patients have had a minimum potential follow-up of 4 years from the attainment of a complete response (CR).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To establish the overall survival (OS) rates of patients with newly diagnosed core binding factor (CBF) acute myeloid leukaemia (AML) treated with high-dose cytarabine (Ara-C) containing regimens exclusive of anthracyclines.</outcome>
      <timepoint>The first analysis of OS will take place 12 months after the last-registered patient has commenced treatment.  If appropriate, the final analysis will take place after all patients have had a minimum potential follow-up of 4 years from the attainment of a complete response (CR).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. To estimate the percentage of patients achieving CR with this treatment approach. </outcome>
      <timepoint> For each patient, this will be assessed 50 days post commencement of induction therapy.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. To estimate the leukaemia-free survival (LFS) rate for patients who achieve CR with protocol treatment.</outcome>
      <timepoint>The first analysis of LFS will take place 12 months after the last-registered patient has commenced treatment.  If appropriate, the final analysis will take place after all patients have had a minimum potential follow-up of 4 years from the attainment of a complete response (CR).</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. To determine the safety and tolerability of the protocol treatment.</outcome>
      <timepoint>Monitored continuously and independently reviewed every 6 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>4. To identify the proportion of patients with CBF AML with cryptic rearrangements (cytogenetically silent). </outcome>
      <timepoint>Assessed at diagnosis.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>5. To monitor the levels of CBF fusion transcripts in PB and BM by quantitative real time polymerase chain reaction (Q-PCR) during therapy and remission and hence to establish the kinetics of leukaemia eradication and the threshold or incremental change in transcript levels which correlate with risk of subsequent relapse.</outcome>
      <timepoint>Measured after each treatment and 1 to 3 monthly thereafter for 2 years.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>6. To compare the utility of Q-PCR with interphase fluorescent in-situ hybridisation (i-FISH), conventional cytogenetics, and, where applicable, flow cytometry in detection of minimal residual disease and prediction of relapse risk.</outcome>
      <timepoint>Measured after each treatment and 1 to 3 monthly thereafter for 2 years.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. A morphologic diagnosis of AML by WHO criteria; note that patients with t(8;21) and less than 20% blasts will be included.2. Confirmation of CBF subtype by cytogenetic finding of t(8;21) or inv(16) or t(16;16) (either alone or in combination with other cytogenetic abnormalities) or PCR evidence of a CBF fusion transcript 3. ECOG performance status 0 to 3; 4. Written informed consent prior to registration 5. Potentially childbearing patients must use effective contraception 6. Patients must be registered prior to the commencement of induction therapy.</inclusivecriteria>
    <inclusiveminage>15</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Serious cardiac or pulmonary dysfunction precluding the delivery of the proposed therapy2. Severe renal dysfunction3. Severe hepatic dysfunction including bilirubin &gt; 2.5 ULN unless attributable to leukaemia4. Prior treatment for AML5. Contraindication to the use of study drugs6. Known HIV infection7. Pregnancy and lactation8. Inability to comply with study requirements.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>14/12/2004</anticipatedstartdate>
    <actualstartdate>11/02/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate>19/06/2009</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize>53</actualsamplesize>
    <currentsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>31/12/2012</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>Australasian Leukaemia and Lymphoma Group</primarysponsorname>
    <primarysponsoraddress>Level 2, 10 St Andrews Place
East Melbourne Vic 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Leukaemia Foundation of Australia</fundingname>
      <fundingaddress>C/- the ALLG Office, Level 2 10 St Andrews Place East Melbourne 3002</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Amgen Australia</fundingname>
      <fundingaddress>c/- The ALLG Office, Level 2 10 St Andrews Place East Melbourne 3002</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication>None</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Canberra</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Gosford</ethicname>
      <ethicaddress />
      <ethicapprovaldate>12/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hobart</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Brisbane</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mater Newcastle</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Perth</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Sydney</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Paula Marlton</name>
      <address>Oncology/Haematology Unit
Princess Alexandra Hospital
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 32407036</phone>
      <fax>+61 7 32402252</fax>
      <email>paula_marlton@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Paula Marlton</name>
      <address>Oncology/Haematology Unit
Princess Alexandra Hospital
Ipswich Road
Woolloongabba QLD 4102</address>
      <phone>+61 7 32407036</phone>
      <fax>+61 7 32402252</fax>
      <email>paula_marlton@health.qld.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>